Project Grant K23HL171910
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$194K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), is funding research aimed at generating comparative effectiveness evidence for the use of guideline-directed medical therapies (GDMT) in heart failure patients with mid-range ejection fraction (HFMREF). The $777,674 award to the Massachusetts General Hospital (MGH) will enable the creation of a large echocardiography registry to apply...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $198,936 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to New York University School of Medicine (NYU) for the purpose of studying the impact of restrictive drug coverage policies on heart failure care. The project aims to quantify the effects of cost-sharing requirements and prior authorization policies on provider prescribing practices, patient medication adherence, and clinical outcomes for guideline-recommended...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $169,416 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to evaluate the impact of recent Medicare policy changes on heart failure outcomes among Medicare beneficiaries.
The key objectives are to:
Determine if health care access, affordability, and clinical outcomes differ between Medicare beneficiaries with heart failure...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,250,934.00 to the Regents of the University of Michigan to conduct research on the metabolic and mechanical determinants of reserve cardiac power output. The overarching goals are to understand the physiological limitations to cardiac power and output reserve, and how these contribute to diminished left-ventricular power output and...
This $249,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports a late-stage implementation strategy for a "heart failure (HF) polypill" in India. The primary objectives are to: 1) conduct formative mixed methods research to guide development of the HF polypill strategy; 2) evaluate if the HF polypill implementation strategy can reduce cardiovascular disease mortality and HF...
This federal Project Grant award, R01HL174691, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $809,029 award will fund a 5-year randomized controlled trial to evaluate the effectiveness of gamification and social incentives in increasing physical activity adherence among patients with heart failure with preserved ejection fraction (HFPEF). The study aims to determine if this low-cost, scalable...
This $735,346 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund the development of an AI-powered, equitable, interpretable, and generalizable cardiovascular disease (CVD) risk prediction model. The primary awardee is the University of Massachusetts Medical School, which will partner with community health centers and academic hospitals to integrate clinical factors and multi-domain social...
The University of Colorado-Denver received a $117,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant, which will run from May 1, 2024 to April 30, 2026, will fund a pre-implementation study to assess best practices and organizational processes needed to decrease caregiver requirements for patients receiving heart replacement therapies, such as heart transplants and left ventricular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $117,789 to the Regents of the University of Minnesota to conduct research on the role of resistance exercise in the prevention and treatment of heart failure with preserved ejection fraction (HFpEF).
The primary objectives are to: 1) elucidate the independent effects of resistance exercise on HFpEF primary and secondary...
This $1,093,397 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel statistical and machine learning methods to characterize glucose metabolism and blood pressure data from wearable medical devices. The principal objective is to create algorithms that can better exploit continuous glucose monitor (CGM) and ambulatory blood pressure monitor (ABPM) data to enable...